CoronaVac has 78% efficiency against COVID-19

CoronaVac, the vaccine against the novel coronavirus produced by Butantan Institute in partnership with Chinese pharmaceutical company Sinovac has a minimum efficiency of 78 percent. The announcement was made today (Jan. 7) by the São Paulo state government during a press conference.

This percentage, the government stated, stems from studies conducted in Brazil with health professionals, who are more exposed to the virus.

The vaccine is reported to have guaranteed total protection against serious cases and deaths caused by the disease. “This means that it has raised the level of efficiency and efficacy to protect against COVID-19 [the disease caused by the new coronavirus,” São Paulo Governor João Doria said today (7). “People immunized with the Butantan vaccine will have 78–100 percent less chance of developing COVID-19 than someone who does not receive the vaccine.”

The efficiency data were reviewed by an international committee. They are being disclosed today at a meeting with Brazil’s sanitary regulator Anvisa, tasked with approving the use of the vaccine in the country. The minimum efficiency rate recommended by Anvisa itself is 50 percent.